Dr. Rekha Bansal is a highly skilled Medical Oncologist with over 8+ years of experience in the field, dedicated to providing comprehensive care for patients battling cancer. Based at Apollo Health City, Jubilee Hills, Hyderabad, she has established a reputation for her compassionate approach and commitment to patient-centered treatment. Dr. Bansal specializes in the management of a wide range of solid tumors, offering advanced chemotherapy, immunotherapy, and targeted therapy protocols tailored to each patient's unique needs. Dr. Bansal holds a distinguished qualification of DM in Medical Oncology, which underlines her advanced expertise and deep specialization in the complexities of cancer care. She is well-versed in multidisciplinary cancer treatment, working alongside surgical and radiation oncology teams to develop individualized treatment plans. With extensive training and experience in managing malignancies including breast cancer, lung cancer, gastrointestinal cancers, head and neck cancers, and sarcomas, Dr. Bansal is committed to the latest evidence-based practices and emerging advancements in oncological care. She is an excellent choice for international patients seeking world-class oncology expertise at a leading healthcare facility in India.
- Medical Oncology
- Chemotherapy for Solid Tumors
- Adjuvant Chemotherapy
- Neoadjuvant Chemotherapy
- Palliative Chemotherapy
- Immunotherapy for Solid Tumors
- Immune Checkpoint Inhibitor Therapy
- Hormone Therapy for Breast Cancer
- Targeted Therapy for Solid Tumor Cancers
- Molecular Targeted Therapy
- Biomarker-Based Targeted Therapy
- HIPEC
- DM (Medical Oncology)
- DNB (General Medicine)
- MBBS
Dr. Rekha Bansal brings over 8 years of dedicated experience in the field of Medical Oncology. She currently serves as a Consultant in Medical Oncology at Apollo Health City, Jubilee Hills, Hyderabad.
- Apollo Health City, Jubilee Hills
- A clinicopathological profile of lung cancer at a tertiary care center, Indian Journal of Cancer (DOI: 10.4103/0019-509X)
- A case of splenoblastoma/concomitant malignant lymphoproliferative individual, Global Journal of Hematology and Blood Transfusion (2019)
From your first enquiry to recovery back home — we manage every detail so you can focus on getting better.
Join 5,000+ patients from 40+ countries who chose world-class care at a fraction of the cost.
